Business context and reporting period
Filing identity differs from request metadata: the supplied filing is Angion Biomedica Corp. (Nasdaq: ANGN), not Elicio Therapeutics, Inc. It is the annual report for the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter financial statements.
Angion is a clinical-stage biotechnology company with no approved products or product sales. Its lead candidate, ANG-3070, is in a Phase 2 kidney-disease trial; the company also has preclinical ROCK2 and CYP11B2 programs. Following disappointing ANG-3777 trial results, ANG-3070 became the primary development focus.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $28.3 million | $2.9 million |
| Operating expenses | $67.6 million | $58.2 million |
| Loss from operations | $39.3 million | $55.3 million |
| Net loss | $54.6 million | $80.1 million |
| Net loss per share, basic and diluted | $1.93 | $5.43 |
| Cash used in operating activities | $52.6 million | $22.9 million |
Revenue was contract revenue from the Vifor license and government grants, not product sales. Operating margin is not a meaningful indicator for this pre-revenue company. The 2021 net loss included $15.3 million of net other expense, including fair-value changes and interest expense.
At year-end, cash and cash equivalents were $88.8 million, total assets $96.5 million, total liabilities $15.0 million, and stockholders’ equity $81.5 million. Current assets of $91.2 million exceeded current liabilities of $11.3 million. The company reported no convertible notes or preferred stock outstanding after their conversion in the February 2021 IPO. Remaining lease liabilities were $4.4 million and financing obligations were $0.3 million.
The IPO and concurrent Vifor private placement generated approximately $107.0 million in net proceeds. Management said existing cash was expected to fund planned operations well into 2023, while cautioning that projections depend on uncertain assumptions and additional capital may be required.
Material changes versus the prior year
- Revenue rose by $25.4 million, mainly because Angion recognized $27.5 million of Vifor contract revenue in 2021, versus $0.2 million in 2020. A change in estimated costs and performance period contributed $24.2 million of additional 2021 revenue and reduced the reported net loss by the same amount.
- Research and development expense increased 24.9% to $48.7 million, primarily from higher personnel costs and clinical activity. General and administrative expense was broadly stable at $18.5 million.
- Net loss narrowed by $25.5 million, but operating cash use increased by $29.8 million.
- The February 2021 IPO converted outstanding convertible notes and preferred stock into common shares and materially strengthened cash and equity.
Outlook, risks and unusual items
- Angion planned to report JUNIPER Phase 2 topline data in the first half of 2023 and to file an IND for ANG-3070 in idiopathic pulmonary fibrosis by the end of 2022. It also aimed to select at least one preclinical lead and begin IND-enabling work by year-end 2022. These are forward-looking plans, not assured outcomes.
- Neither ANG-3777 trial reported in late 2021 met its primary endpoint. Angion did not plan further trials under the existing development plan and did not expect further Vifor milestones or royalties; closeout analyses and discussions with Vifor were ongoing.
- On January 4, 2022, the company announced a workforce reduction affecting somewhat less than half of employees. Subsequent separation agreements disclosed approximately $1.1 million in benefits for former executive Itzhak Goldberg and $0.5 million for another former employee.
- Management identified material weaknesses in financial reporting controls, including insufficient U.S. GAAP expertise for complex transactions and inadequate period-end accrual and contractor-deliverable review controls. Disclosure controls and internal control over financial reporting were assessed as ineffective at year-end; remediation was ongoing. The auditor issued an unqualified opinion on the financial statements but did not audit internal control effectiveness.
- Key risks include clinical failure or delays, COVID-19 and regional conflict affecting trial sites in Eastern Europe, dependence on single-source manufacturers and contractors, need for additional capital, regulatory uncertainty, competition, and intellectual-property risks. No material legal proceedings were reported.
Important facts for investors to verify
- Confirm the filing entity: the source is Angion Biomedica Corp., not Elicio Therapeutics, Inc.
- Review the Vifor revenue-recognition estimate change: it added $24.2 million to 2021 revenue and reduced net loss by $24.2 million.
- Track ANG-3070 trial progress, enrollment, safety findings, and whether the stated data and IND milestones were met.
- Assess cash burn against management’s “well into 2023” funding estimate and the potential need for dilutive financing.
- Monitor remediation of the disclosed material weaknesses and the effects of the workforce reduction on operations and trial execution.